The second standard: peptide sourcing.
Sourcing documentation is the weakest link in peptide supply, and nobody verifies it. We intend to change that — after the first standard is published.
Regenerative Aesthetics and Longevity Wellness Standard.
Published. Founding cohort in progress.
Certification →Peptide Sourcing Standard.
Scoping. Criteria not drafted. No application open. Targeted 2027.
Status as of 17 November 2026. This page is updated as the program advances.
One standard at a time.
The first standard is being written now, with a founding cohort, a committee structure and a published revision process. A second standard inherits all of it: the same vocabulary, the same evidence discipline, the same cycle of revision.
Written at the same time, both would compete for the same attention and the same committee, and we would end up with two weak documents instead of one strong one and a credible successor to it.
We are not taking peptide applications, and will not until the first standard has been published, applied to a full cohort, and revised at least once.
The requirement exists. The verification does not.
Federal policy governing the compounding of certain substances is conditioned on registered facilities and on a valid certificate of analysis held for each bulk substance. Purchasers are expected to hold that documentation for the material they buy.
No independent party checks whether they do, or whether what they hold is adequate to the claim it makes. The documentation requirement largely exists already. The review of it does not.
RCX would verify. It would not invent a new requirement, and it would not restate an existing one as if it were ours.
What it would likely cover.
Scope is not final. This is where the work is pointed today.
- 01Supplier qualification and ongoing supplier review
- 02Certificate of analysis review: what is on it, what is missing, what to reject
- 03Independent verification testing and when it is warranted
- 04Chain of custody from manufacturer to end user
- 05Storage, handling and cold chain
- 06Labeling, lot traceability and recordkeeping
- 07Written procedures for refusing or quarantining material
- 08Personnel training on all of the above
What this standard will not do.
The standard addresses how an organization sources, documents and handles material. It takes no position on whether any substance may lawfully be compounded, dispensed, prescribed or administered, by whom, or to whom.
Those questions are determined by federal and state law and by the licensing boards, and they are not ours to answer.
Certification under this standard is not a finding of legality, safety or efficacy, and is not a substitute for a facility’s own legal and regulatory counsel.
A certification that blurred that line would be worse than useless.
Four roles in the chain.
Laboratories
The party that makes the material and holds the documentation behind it.
Compounding pharmacies
The party that prepares and dispenses, and answers for what it sources.
Distributors
The party that moves material between manufacturer and end user, and holds the chain of custody.
Prescribing clinicians
The party who signs, and who carries responsibility for what sits behind the signature.
Register interest.
Registering interest adds an organization to a notification list. It is not an application. It confers no priority, no preference, no reduced standard and no guarantee of any certification outcome.
Criteria do not exist yet. When they do, every organization will be assessed against them on the same terms.
First the standard that is live. Then this one.
The RCX Standard →